GAO: 340B pro­gram net­ted sav­ings and pro­vid­ed ben­e­fits for low-in­come pa­tients

As phar­ma com­pa­nies and in­dus­try groups seek lim­its on the 340B pro­gram, a new re­port from the GAO ex­am­ined hos­pi­tals that re­ceived the pan­dem­ic’s el­i­gi­bil­i­ty ex­cep­tion and some of the sav­ings gen­er­at­ed for hos­pi­tals that par­tic­i­pate in the pro­gram.

The 340B pro­gram re­quires phar­ma com­pa­nies to sell out­pa­tient drugs at dis­count­ed prices to cov­ered en­ti­ties, which in­clude cer­tain types of med­ical cen­ters and hos­pi­tals, for the drugs to be cov­ered by Med­ic­aid. In ad­di­tion to hos­pi­tals get­ting sav­ings on the costs of those ther­a­pies, those providers can gen­er­ate rev­enue when pur­chas­ing 340B drugs. Around 2,600 hos­pi­tals were par­tic­i­pat­ing in the pro­gram as of Jan­u­ary.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.